Navigation Links
Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:8/3/2010

NORTHBROOK, Ill., Aug. 3 /PRNewswire/ -- Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by the Company.

Jefferies & Company, Inc. and Piper Jaffray & Co. are acting as joint book-running managers, and JMP Securities LLC and Lazard Capital Markets LLC are acting as co-managers for the offering.  The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to the offering may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022 or at (877) 547-6340.

A registration statement related to these securities has been filed with the SEC, but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Horizon Pharma

Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.  


'/>"/>
SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
2. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
3. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
10. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
(Date:2/26/2015)... February 27, 2015 RnRMarketResearch.com ... market research report to its store. This report ... therapeutic pipeline. The report "Corneal Ulcers - Pipeline ... therapeutic development for Corneal Ulcers. Corneal Ulcers are ... bacterial infections, viral infections & fungal infections. The ...
(Date:2/26/2015)... , Feb. 26, 2015  Today the ... The psychological and physical side effects of pain ... opioid painkillers, such as Vicodin and Oxycontin, are safer ... Americans overdose on prescription painkillers than on heroin and ... and CEO of NSC. "Yet, these medications are marketed ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2
... plc (LSE: SHP, Nasdaq: SHPGY ), the ... INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a ... its primary objective, which was to evaluate the effects ... to 12 years with a diagnosis of ADHD and ...
... MEDRAD Interventional(TM)/Possis(R) today announced that it has ... closer to market as an option for the ... and Europe who suffer from Peripheral Arterial Disease ... investigators for U.S. clinical trials and the completion ...
Cached Medicine Technology:Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 2Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 3Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 4Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 5Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 2Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 3Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 4Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 5
(Date:2/28/2015)... 28, 2015 Mew and Company, a ... they now provide business consulting services in addition to ... tax planning and succession planning. Company finances are a ... professionals. On top of this, complex Canadian tax laws ... accounting. As a result, Mew and Company works to ...
(Date:2/28/2015)... Bethesda, MD (PRWEB) February 28, 2015 ... will present its annual awards at the International Symposium ... Dinner will be held at the Hyatt Regency Bethesda ... honored for their dedicated work and commitment to the ... of the Year Award will be presented to Miriam ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... to discuss federal testosterone lawsuits that have been filed ... scheduled for the second week in March, the Firm ... the Court’s website, parties involved in the federal litigation ... to address matters related to prescription therapy treatments designed ...
(Date:2/28/2015)... The noted Toronto plastic surgeon Dr. ... recently featured in the January/February 2015 issue of Elevate ... Ellis was featured in an article entitled “Get the ... that Kim Cattrall has possibly undergone to maintain her ... smooth without horizontal lines or frown line creases, which ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous announcement ... reader named Guardian 2. The correct product name ... scanner that significantly increases the complexity of security ... scanner provides fast and easy access for both ... lockers with Vanguard technology tracks inventory by ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... February 02, 2009 A new study published in ... of migraine in the U.S. and recent clinical findings ... study traces the history of economic articles published on ... of relevant articles to identify possible health risks associated ...
... consumer group today called upon Google to publicly disclose ... of the financial stimulus legislation, given a new account ... bill was felt on Capitol Hill.Consumer Watchdog called on ... letter follows:Robert Boorstin , Director of Corporate and Policy ...
... Rochester Medical Corporation (Nasdaq: ROCM ) today announced ... Company reported sales of $8,436,000 for the current quarter compared ... It also reported net income of $54,000 or $.00 per ... per diluted share for the first quarter of last year.The ...
... Tobacco use narrows blood vessels to fetus, study finds ... linking smoking during pregnancy to low birth weight has ... smoking during pregnancy lowers production of an enzyme called ... dilation. Reduced production of eNOS causes narrowing of blood ...
... getting them, study shows , , MONDAY, Feb. 2 (HealthDay ... may be popping vitamins and mineral supplements they don,t ... and mineral supplements are not considered necessary when a ... hand, children who actually need these supplements -- those ...
... adults who are heavy users of marijuana are ... development, according to a new study. Pediatric researchers ... interconnect brain regions involved in memory, attention, decision-making, ... of particular concern because adolescence is a crucial ...
Cached Medicine News:Health News:Study reviews health risks, economic burden of migraine 2Health News:Consumer Watchdog to Google: Publicly Disclose Your Lobbying Positions on Electronic Medical Record Provisions in Stimulus Bill 2Health News:Rochester Medical Reports First Quarter Results 2Health News:Rochester Medical Reports First Quarter Results 3Health News:Rochester Medical Reports First Quarter Results 4Health News:Rochester Medical Reports First Quarter Results 5Health News:Rochester Medical Reports First Quarter Results 6Health News:Rochester Medical Reports First Quarter Results 7Health News:Rochester Medical Reports First Quarter Results 8Health News:Smoking-Low Birth Weight Link Explained in Part 2Health News:Many Kids Don't Need the Vitamins They're Taking 2Health News:Many Kids Don't Need the Vitamins They're Taking 3Health News:Heavy marijuana use may damage developing brain in teens, young adults 2
... The Aircast Knee Immobilizer is designed to ... rigid posterior splint comfortably stabilizes the knee ... provide a space behind the knee, even ... lightweight design, and non-slip comfort, the Knee ...
Designed to provide continuous cold therapy to the shoulder and back. Helps to reduce pain and swelling and speed rehab....
Indicated for treatment of patella instability...
OmoTrain is a unique support for the shoulder that promotes mobility and limits rotation....
Medicine Products: